Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
BUSINESS
Tecentriq/Cabometyx Cuts Risk of Disease Progression or Death by 35% in CRPC
A combination therapy pairing Takeda Pharmaceutical’s tyrosine kinase inhibitor Cabometyx (cabozantinib) and Chugai Pharmaceutical’s PD-L1 inhibitor Tecentriq (atezolizumab) reduced the risk of disease progression or death by 35% in certain prostate cancer patients, according to the latest data update. The…
To read the full story
Related Article
- Tecentriq/Cabometyx Combo Extends PFS in Prostate Cancer Trial: Takeda
August 23, 2023
- Chugai, Takeda to Join Global PIII of Tecentriq/Cabometyx Combo in Japan
September 11, 2020
BUSINESS
- Nipro Eyes 50-60 Stemirac Treatment Sites across Japan after Full Nod
November 20, 2026
- AstraZeneca’s Etcamah to Hit Japan Market on Nov. 27
November 20, 2026
- Japan Drug Makers’ Sales Seen Dipping in FY2026 on Co-Marketing Exits
November 20, 2026
- J&J’s Icotyde Could Broaden Psoriasis Treatment Options: Expert
November 20, 2026
- Nippon Kayaku to Acquire AstraZeneca’s Zoladex on Dec. 16
November 20, 2026





